GlobeNewswire: Pieris Pharmaceuticals, Inc. Contains the last 10 of 16 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:02:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/11/08/1647914/0/en/Pieris-Pharmaceuticals-to-Present-at-Investor-Conferences-in-November.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Present at Investor Conferences in November2018-11-08T13:00:00Z<![CDATA[BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the following investor conferences in November:]]>https://www.globenewswire.com/news-release/2018/11/07/1646825/0/en/Pieris-Pharmaceuticals-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update2018-11-07T12:00:00Z<![CDATA[Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST]]>https://www.globenewswire.com/news-release/2018/10/31/1640143/0/en/Pieris-Pharmaceuticals-to-Host-Third-Quarter-2018-Investor-Call-and-Corporate-Update-on-November-7-2018.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 20182018-10-31T12:00:00Z<![CDATA[BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a third quarter 2018 investor call on Wednesday, November 7, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2018/10/25/1627092/0/en/Pieris-Pharmaceuticals-Appoints-Matthew-L-Sherman-M-D-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors2018-10-25T12:16:09Z<![CDATA[BOSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Matthew L. Sherman, M.D., has joined the Company’s Board of Directors.]]>https://www.globenewswire.com/news-release/2018/10/02/1588521/0/en/Pieris-Pharmaceuticals-to-Present-Preclinical-Data-for-4-1BB-PD-L1-Bispecific-PRS-344-ONC0055-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting2018-10-02T12:00:00Z<![CDATA[BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical data for PRS-344/ONC0055 will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C. PRS-344/ONC0055 is one of currently five programs Pieris is developing as part of its immuno-oncology collaboration with Servier.]]>https://www.globenewswire.com/news-release/2018/09/25/1575621/0/en/Pieris-Pharmaceuticals-to-Present-at-Investor-Conferences-in-October.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Present at Investor Conferences in October2018-09-25T12:00:00Z<![CDATA[BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the following upcoming investor conferences in October:]]>https://www.globenewswire.com/news-release/2018/09/14/1571068/0/en/Pieris-Pharmaceuticals-to-Present-Preclinical-Data-for-Inhaled-IL-4R%CE%B1-Antagonist-AZD1402-PRS-060-at-the-ERS-International-Congress-2018.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 20182018-09-14T12:00:00Z<![CDATA[BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical data for AZD1402/PRS-060 will be presented at two poster sessions at the European Respiratory Society (ERS) International Congress 2018 in Paris, France. PRS-060, an inhaled IL-4 receptor alpha antagonist, the lead candidate in Pieris’ respiratory collaboration with AstraZeneca, is currently in Phase 1 clinical development.]]>https://www.globenewswire.com/news-release/2018/09/10/1568488/0/en/Pieris-Pharmaceuticals-Appoints-Peter-Kiener-D-Phil-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors2018-09-10T12:00:00Z<![CDATA[BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Peter Kiener, D.Phil. has joined the Company’s Board of Directors.]]>https://www.globenewswire.com/news-release/2018/09/04/1564834/0/en/Pieris-Pharmaceuticals-Announces-Dosing-of-First-Patient-in-Phase-I-Combination-Trial-for-PRS-343-Plus-Anti-PD-L1-Immunotherapy.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy2018-09-04T12:00:00Z<![CDATA[BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate targeting HER2 and 4-1BB, plus atezolizumab (Tecentriq®), an approved PD-L1 inhibitor.]]>https://www.globenewswire.com/news-release/2018/08/30/1563313/0/en/Pieris-Pharmaceuticals-to-Present-at-the-20th-Annual-Rodman-Renshaw-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=47652Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference2018-08-30T12:00:00Z<![CDATA[BOSTON, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Stephen Yoder, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5th at 12:05PM EDT at the St. Regis New York Hotel in New York. A webcast of the Company’s presentation will be available at this link.]]>